Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 177, Issue 1-2, Pages 161-166Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2006.04.024
Keywords
glatiramer acetate; anti-GA antibodies; IgG1/IgG2/IgG3/IgG4; Th-1/Th-2; IgG secretion in vitro; IgG in serum; primary progressive multiple sclerosis
Categories
Ask authors/readers for more resources
In this study we analyzed the humoral immune response to glatiramer acetate in 16 GA-treated primary progressive MS patients and 9 placebo patients from the PROMiSe study. We have demonstrated that all multiple sclerosis patients (n = 16) continuously treated with GA for 3 years developed anti-GA antibodies that peaked at month 3 and remained elevated during the whole study. We have also demonstrated that initially GA-reactive antibodies of the IgG1 subclass predominate, peaking at month 9 of therapy, but after 9 months IgG1 decreases while anti-GA antibodies of the IgG4 subclass increase and remain high for the 3 years of follow-up. These results support a shift from Th-1 to Th-2 in the antibody response to glatiramer acetate treatment. (c) 2006 Elsevier B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available